Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 3/2010

01-05-2010

Emerging Therapies in Castrate-Resistant Prostate Cancer

Authors: Luai Zarour, Joshi Alumkal

Published in: Current Urology Reports | Issue 3/2010

Login to get access

Abstract

Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.
Literature
1.
2.
Mohler JL, Gregory CW, Ford OH 3rd, et al.: The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004, 10:440–448.CrossRefPubMed
3.
Mostaghel EA, Page ST, Lin DW, et al.: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007, 67:5033–5041.CrossRefPubMed
4.
Taplin ME: Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007, 4:236–244.CrossRefPubMed
5.
Eisenberger MA, Simon R, O’Dwyer PJ, et al.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin Oncol 1985, 3:827–841.PubMed
6.
Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506–2513.PubMed
7.
Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756–1764.PubMed
8.
Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–1520.CrossRefPubMed
9.
Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–1512.CrossRefPubMed
10.
Rosenberg JE, Weinberg VK, Kelly WK, et al.: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556–563.CrossRefPubMed
11.
Potter GA, Barrie SE, Jarman M, Rowlands MG: Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995, 38:2463–2471.CrossRefPubMed
12.
• Attard G, Reid AH, A’Hern R, et al.: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27:3742–3748. This report describes a phase I/II clinical trial with abiraterone acetate in CRPC.CrossRefPubMed
13.
Danila DC, Bono JD, Ryan CJ, et al.: Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): impact of prior ketoconazole (keto). J. Clin Oncol 2009, 27:15s.CrossRef
14.
Reid AH, Attard G, Danila D, et al.: A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 2009, 27:15s.CrossRef
15.
Efstathiou E, Wen S, Molina A, et al.: Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). In 2009 Genitourinary Cancers Symposium.
16.
• Tran C, Ouk S, Clegg NJ, et al.: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787–790. This report describes the preclinical findings with MDV3100 in prostate cancer model systems and summarizes some of the clinical findings from the recently completed phase I trial in CRPC. CrossRefPubMed
17.
Scher HI, Beer TM, Higano CS, et al.: Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 2009 27:15 s.CrossRef
18.
Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459–5468.CrossRefPubMed
19.
Duvic M, Talpur R, Ni X, et al.: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31–39.CrossRefPubMed
20.
Chen L, Meng S, Wang H, et al.: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005, 4:1311–1319.CrossRefPubMed
21.
Gibbs A, Schwartzman J, Deng V, Alumkal J: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A 2009, 106:16663–16668.CrossRefPubMed
22.
Marrocco DL, Tilley WD, Bianco-Miotto T, et al.: Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007, 6:51–60.CrossRefPubMed
23.
Bradley DA, Dunn R, Rathkopf D, et al.: Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. In 2008 Genitourinary Cancers Symposium.
24.
Hussain M, Dunn R, Rathkopf D, et al.: Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): a phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862). J Clin Oncol 2007, 27:13:2278–2287.
25.
Parker C, Molife R, Karavasilis V, et al.: Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 2007, 25:18s.
26.
Rathkopf DE, Chi KN, Vaishampayan U, et al.: Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 2009, 27:15s.CrossRef
27.
Gera JF, Mellinghoff IK, Shi Y, et al.: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004, 279:2737–2746.CrossRefPubMed
28.
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348–355.CrossRefPubMed
29.
McMenamin ME, Soung P, Perera S, et al.: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59:4291–4296.PubMed
30.
Neshat MS, Mellinghoff IK, Tran C, et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98:10314–10319.CrossRefPubMed
31.
Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278–2287.CrossRefPubMed
32.
George DJ, Armstrong AJ, Creel P, et al.: A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC). In 2008 Genitourinary Cancers Symposium.
33.
Ross R, Manola J, Oh W, et al.: Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008, 26.
34.
Wagner AJ, Hoff DHV, LoRusso PM, et al.: A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin Oncol 2009, 27:15s.CrossRef
35.
36.
• Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123–134. This report describes the clinical experience from a clinical trial with the PARP inhibitor olaparib. CrossRefPubMed
37.
Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913–917.CrossRefPubMed
38.
Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917–921.CrossRefPubMed
39.
O’Shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27:18s.CrossRef
40.
Madan RA, Arlen PM, Mohebtash M, et al.: Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009, 18:1001–1011.CrossRefPubMed
41.
Kantoff PW, Glode LM, Tannenbaum SI, et al.: Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2006, 24:18s.CrossRef
42.
Kantoff PW, Schuetz T, Blumenstein BA, et al.: Overall survival analysis of a phase II randomized controlled trial of a poxviral based PSA targeted immunotherapy in metastatic castration resistant prostate cancer In 2009 ASCO Annual Meeting.
43.
Antonarakis ES, Carducci MA, Eisenberger MA: Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 Aug 28 (Epub ahead of print).
44.
Small EJ, Fratesi P, Reese DM, et al.: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894–3903.PubMed
45.
Small EJ, Schellhammer PF, Higano CS, et al.: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089–3094.CrossRefPubMed
46.
Dendreon, Inc.: Summary of phase 3 IMPACT trial results. Presented at AUA Meeting 2009.
47.
Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001, 19:565–594.CrossRefPubMed
48.
Small E, Higano C, Tchekmedyian N, et al.: Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 2006, 24:18s.CrossRef
49.
Beer TM, Slovin SF, Higano CS, et al.: Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008, 26.
50.
Slovin SF, Beer TM, Higano CS, et al.: Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009, 27:15s.CrossRef
Metadata
Title
Emerging Therapies in Castrate-Resistant Prostate Cancer
Authors
Luai Zarour
Joshi Alumkal
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 3/2010
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0104-x

Other articles of this Issue 3/2010

Current Urology Reports 3/2010 Go to the issue

ReviewPaper

Technological Advances in Radiation Therapy for Prostate Cancer

ReviewPaper

Prostate Cancer Screening: What We Have Learned from the PLCO and ERSPC Trials

ReviewPaper

A Review of Methods for Hemostasis and Renorrhaphy After Laparoscopic and Robot-assisted Laparoscopic Partial Nephrectomy

ReviewPaper

Focal Cryotherapy for Prostate Cancer

ReviewPaper

Active Surveillance for Prostate Cancer: A Review

ReviewPaper

Factors Predicting Early Return of Continence After Radical Prostatectomy